Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
eps-chart

PFE EPS

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for Pfizer's (PFE) EPS in Q4'25 shows a value of -0.29 USD, indicating a quarterly loss and marking a downturn from the positive figures in the preceding three quarters of 2025. This negative EPS contrasts with the earlier recovery trend observed in Q1'25 (0.52 USD), Q2'25 (0.51 USD), and Q3'25 (0.62 USD), suggesting potential challenges in profitability for the period ending December 2025. Over the timeframe from Q1'23 to Q4'25, PFE's EPS exhibits high volatility with an overall declining trend, starting at 0.98 USD in Q1'23 before plunging to losses of -0.42 USD in Q3'23 and -0.59 USD in Q4'23, followed by a partial rebound to peaks of 0.79 USD in Q3'24 and 0.62 USD in Q3'25, only to revert to negative territory in Q4'25. Year-over-year EPS growth mirrors this instability, with sharp declines exceeding -100% in Q3'23 and Q4'23, a notable surge to +288% in Q3'24, and a dramatic -514% drop in Q4'25, highlighting significant inflection points driven by operational or market factors. The bar chart for EPS and line overlay for growth underscore persistent fluctuations, advising analysts to monitor upcoming quarters for stabilization.